Oxthera News

Hugo Petit Appointed CFO of OxThera

Press release Stockholm, Sweden, September 7, 2018 Hugo Petit Appointed CFO of OxThera Stockholm – 7  September 2018 – OxThera […]

OxThera updates on Phase 3 study with Oxabact® in Primary Hyperoxaluria

Press release Stockholm, Sweden, July 5, 2018 OxThera updates on Phase 3 study with Oxabact® in Primary Hyperoxaluria OxThera AB, […]

OxThera announces the appointment of Dr Alain Munoz to its Board of Directors

Press release Stockholm, Sweden, June 13, 2018 OxThera announces the appointment of Dr Alain Munoz to its Board of Directors Stockholm […]

OxThera announces the randomization of the first patient into its phase III EPHEX study with Oxabact

Press release Stockholm, Sweden, 15 March 2018  OxThera announces the randomization of the first patient into its phase III EPHEX […]

OxThera Strengthens Patent Portfolio for treatment of Hyperoxaluria

Press release Stockholm, November 9, 2017 OxThera Strengthens Patent Portfolio for treatment of Hyperoxaluria OxThera AB announced today that it […]

OxThera appoints new Chief Medical Officer

Press release Stockholm, Sweden, Oct 12, 2017 Dr Bastian Dehmel Appointed CMO of OxThera. Stockholm – 12 October 2017 – […]

OxThera announces new CEO

Press release Stockholm, Sweden, July 5, 2017 Matthew Gantz Appointed CEO of Oxthera. Stockholm – 5 July 2017 – OxThera […]

OxThera Raises EUR 32 Million to Complete Development of Oxabact® for Treatment of Primary Hyperoxaluria

November 29, 2016 OxThera AB, a Stockholm-based privately-held biopharmaceutical company, announces today that it has agreed on a EURO 32 […]

Oxabact® granted EMA Orphan Drug Designation for treatment of SBS

OxThera AB announced today that its product Oxabact® has been granted an Orphan Drug Designation in the European Union for […]

OxThera Strengthens Patent Portfolio for treatment of Hyperoxaluria

OxThera AB announced today that it has been granted two new US patents and one new Australian patent during the […]

EXTERNAL NEWS